Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

NCT00250874 is registered in ClinicalTrials.gov with Zeneus Pharma as lead sponsor.

NCT NCT00250874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00250874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Lead sponsor
Zeneus Pharma
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2003
Completion date
Not reported
Enrollment
45
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer